Inclusion criteria

 
The main function of this Web page is to encourage scientists worldwide to speak the same language and to avoid "home-made" allelic designations that can confuse the nomenclature system and the scientific literature, and it contains the recommended nomenclature for the human polymorphic CYP genes. It adheres to the guidelines provided in Shows et al (1987), Daly et al (1996), Antonarakis and the Nomenclature Working Group (1998) and den Dunnen and Antonarakis (2001) as detailed below:

 

  1. On this website only human CYP alleles are considered. 
  2. The gene and allele is separated by an asterisk followed by Arabic numerals and upper-case Roman letters with less than four characters to name the allele (e.g. CYP1A1*3, CYP1B1*22, CYP2D6*10B). 
  3. A gene is considered as the sequence from 5 kb upstream from the transcription start site to 500 bp downstream of the last exon. However, if a regulatory element has been characterised at a more distant part of the gene, also this area belongs to the gene. 
  4. To be assigned as a unique allele it should contain nucleotide changes that have been shown to affect transcription, splicing, translation, posttranscriptional or posttranslational modifications or result in at least one amino acid change. 
  5. Additional nucleotide changes and combinations of nucleotide changes in the gene will be given letters (e.g. *21A, *21B). Thus, in cases where silent mutations occur or mutations are present in regulatory parts or introns with unclear function, the allelic name should adhere to the closest functionally characterised allele by subgroup assignments such as CYP2D6*4A. Allelic variants can be defined as combinations of up to three letters (e.g. CYP2D6*2ABC), thereby allowing room for 22 x 22 x 22 = 10,648 different variants for each allelic number. The letters I, O, X and Y are excluded because of indexing problems.
  6. For extra gene copies (n) placed in tandem the entire allelic arrangement should be referred to as e.g. CYP2D6*2Xn. 
  7. Numbering of nucleotides in the allele should be as described in Antonarakis and the Nomenclature Working Group (1998). The base A in the initiation codon ATG is denoted +1 and the base before A is numbered -1. 
  8. For reasons of indexing, the names for proteins should have a period between the name of the gene product and number (e.g. CYP2D6.2A).
  9. SNPs that are not easily assigned to a specific allele, will be listed at the bottom of the corresponding nomenclature page with relevant literature references.
  10. Submission of new alleles should be done with information sufficient to fulfil the criteria to be assigned a unique allele as under # 4 above or a letter as described under # 5 above. For incorporation into the Web page as a unique allele, all exons and exon-intron borders should have been sequenced. If a new allele has been detected on the cDNA level, verification of the mutation(s) on the genomic level is required. For acceptance of a new SNP given a separate letter, evidence for its presence on the genomic level is required. 
  11. No temporary allelic numbers or letters are provided, and information about any new allele submitted, will continuously be published on the web Page. In case an author does not want to release the information on the web page before publication, the Webmaster can usually provide him or her with an allelic designation but not release the information on the web page until the manuscript has been accepted or published. 

 

 


Home Page Inclusion criteria
CYP1A1 CYP1A2 CYP1B1 CYP2A6 CYP2A13 CYP2B6 CYP2C8 CYP2C9 CYP2C19 CYP2D6 CYP2E1 CYP2F1 CYP2J2
CYP2R1 CYP2S1 CYP2W1 CYP3A4 CYP3A5 CYP3A7 CYP3A43 CYP4A11 CYP4A22 CYP4B1 CYP5A1 CYP8A1 CYP19A1 CYP21A2 CYP26A1 POR

 This page was updated 13-Nov-2007 by Sarah C Sim
Questions and comments are always welcome